(Q37082785)

18 August 2017

CD70 as a therapeutic target in human malignancies (English)

1 reference

18 August 2017

Iqbal S Grewal

1

1 reference

PubMed ID

18269343

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Expert Opinion on Therapeutic Targets

18 August 2017

1 reference

18 August 2017

12

1 reference

18 August 2017

3

1 reference

18 August 2017

341-351

1 reference

Signalling pathways of the TNF superfamily: a double-edged sword

18 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

The TNF and TNF receptor superfamilies: integrating mammalian biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Humoral immune responses in CD40 ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Identification of a novel subpopulation of germinal center B cells characterized by expression of IgD and CD70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD70 represents the human ligand for CD27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27: marker and mediator of T-cell activation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27-CD70 interactions regulate B-cell activation by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27 is required for generation and long-term maintenance of T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Pathophysiology of Hodgkin's disease: functional and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Aberrant expression and reverse signalling of CD70 on malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Clonal evolution of a follicular lymphoma: evidence for antigen selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD70: a new tumor specific biomarker for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Rituximab therapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Renal Cell Carcinoma Induces Prostaglandin E2 and T-Helper Type 2 Cytokine Production in Peripheral Blood Mononuclear Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

Comparative molecular modelling of the Fas-ligand and other members of the TNF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.341

10.1517/14728222.12.3.341

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18269343